drugset / Trial / NCT07107529
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
Phase 2
Recruiting
150 enrolled
European Myeloma Network B.V.
EMN Trial Office S.r.l. Impresa Sociale · collabHOVON - Dutch Haemato-Oncology Association · collabJanssen Pharmaceutica N.V., Belgium · collabNordic Myeloma Study Group · collabPETHEMA Foundation · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, open-label phase II study with 2 parallel cohorts for frail patients with newly diagnosed multiple myeloma treated with daratumumab in combination with teclistamab and talquetamab. The main purpose of this study is to determine the progression free survival at 18 months in patients treated with teclistamab and daratumumab (Cohort 1) or talquetamab and daratumumab (Cohort 2).
Timeline
- Start
- 2025-12-12
- Primary completion
- 2029-04
- Completion
- 2034-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Talquetamab | Monoclonal antibody | — | Subcutaneous |
| Subject | Teclistamab | Monoclonal antibody | — | Subcutaneous |